Press releaseBusiness Wire
Definium Therapeutics
DFTX · NASDAQ
$35.09+$2.12 (+6.43%)TodayMarket closed ·
Prev close $32.97
Latest news
- Press releaseBusiness Wire
Definium Therapeutics Announces New Employee Inducement Grants
- NewsVandana Singh
Definium Says Its Anxiety Drug Showed 'Unprecedented Efficacy'
- Press releaseBusiness Wire
Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
- Press releaseBusiness Wire
Definium Therapeutics Announces New Employee Inducement Grants
- Press releaseBusiness Wire
Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026
- Press releaseBusiness Wire
Definium Therapeutics to Present Topline Data from Phase 3 Emerge and Voyage Trials Across Major Depressive Disorder and Generalized Anxiety Disorder at Psych Congress 2026
- News
'FDA’s Acting Drug, Vaccine Regulators Tapped for Permanent Roles'- Bloomberg
- Press releaseBusiness Wire
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results
- Press releaseBusiness Wire
Definium Therapeutics Announces New Employee Inducement Grants
- Press releaseBusiness Wire
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events
- Press releaseBusiness Wire
Definium Therapeutics Announces New Employee Inducement Grants
- NewsVandana Singh
Definium Therapeutics Says Unprecedented Efficacy From Anxiety Study 'Raises the Bar'
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseBusiness Wire
Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder
- Press releaseBusiness Wire
Definium Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
- Press releaseGlobe Newswire
A CEO With a Proven Track Record of Success in Growing and Scaling Biopharmaceutical Companies Just Appointed CEO at a Clinical-Stage Biotech, Months Before Its Pivotal Phase 3 Readout
- Press releaseBusiness Wire
Definium Therapeutics Announces New Employee Inducement Grants
- Press releaseBusiness Wire
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
- Press releasePRNewswire
A Depression Drug Just Cleared a Key Hurdle Early, and the Market for New Mental Health Treatments Keeps Widening
- Press releaseBusiness Wire
Definium Therapeutics Announces New Employee Inducement Grants
- Press releasePRNewswire
Big Pharma Just Paid Up to $3.8 Billion for Psychedelic Medicine, and the Rest of the Sector Is Being Repriced in Real Time
- NewsVandana Singh
Why Is GH Research Stock Trading Higher on Thursday?
- Press releaseBusiness Wire
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
- Press releaseBusiness Wire
New Healthcare Claims Study Published in CNS Spectrums Finds High Rates of Treatment Switching, Discontinuation, and Prolonged Gaps in Care Among Patients with Generalized Anxiety Disorder (GAD)
- Press releaseBusiness Wire
Definium Therapeutics Announces New Employee Inducement Grants
- Press releaseGlobe Newswire
Multi-Billion-Dollar Battle for the Future of Depression Treatment Has Begun Creating a Huge Opportunity
- Press releasePRNewswire
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
- Press releaseBusiness Wire
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares
- NewsAvi Kapoor
Acuity Posts Strong Q3 Results, Joins BlackBerry, MillerKnoll, Qualcomm And Other Big Stocks Moving Higher On Thursday
- Press releaseBusiness Wire
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
- NewsVandana Singh
What's Going On With Definium Therapeutics Stock Tuesday?
- News
12 Health Care Stocks Moving In Monday's Intraday Session
- News
Earnings Scheduled For February 26, 2026
- News
Earnings Preview For Definium Therapeutics
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.